tirzepatide age limit What Can You Take Weight Loss Injections? FDA Guidelines What to Know Before Starting

Emphasizing a patch test and close follow-up can help mitigate side effects

What if my prescription needs to be refrigerated

Overweight patients with NAFLD exhibited clinically significant fibrosis (stages F24) at a rate of 20.3%, while obese patients had a slightly higher prevalence at 21.6%

Older adults Drug clearance slows with age

The SURMOUNT-5 trial directly compared tirzepatide against semaglutide for obesity treatment, with tirzepatide achieving 20.2% weight loss versus 13.7% for semaglutide at their respective maximum tolerated doses

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, whereas medications like semaglutide or dulaglutide activate only GLP-1 receptors